Significance of serum thymidine kinase in prediction of the response to therapy in pa-tients with chronic lymphocytic leukemia
The prognostic value of serum thymidine kinase was evaluated in 230 patients with chronic lymphocytic leukemia under different types of modern therapy. Thymidine kinase activity in serum was assessed using radioenzyme methods. It is found that the efficiency of the treatment of patients with chronic lymphocytic leukemia using different chemotherapy and immunochemotherapy’s programs correlates with the content of thymidine kinase in serum. It was demonstrated that the combination of immunochemotherapy RFC eliminates the negative effect of thymidine kinase as a tumor marker from the direct effect of the treatment and the duration of response. The determination of thymidine kinase in the serum among patients with chronic lymphocytic leukemia can be recommended not only as an additional predictor of the disease and response to the therapy, but also for the selection of adequate treatment programs.
About Authors (Correspondence):
Zagoskina T.P. – candidate of medical sciences, assistant professor, head of hematology clinic,
Zotina E.N. – junior researcher of hematology clinic, e-mail: email@example.com
Kryukova M.G. – candidate of medical sciences, researcher of the laboratory of immunology of leukemia
Shardakov V.I. – doctor of medical sciences, professor, head of the laboratory of immunology of leukemia
Grishina I.V. – candidate of medical sciences, assistant professor of the chair of internal diseases